IrrSept vs. Standard of Care in Prevention of Surgical Site Infections
Status: | Recruiting |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/14/2016 |
Start Date: | January 2015 |
End Date: | May 2017 |
Contact: | Page McNeill, BSN |
Email: | pagem@irrisept.com |
Phone: | (855) 704-0263 |
A Phase IV, Multicenter, Prospective, Randomized, Controlled Clinical Study to Compare the IrriSept System Versus Standard of Care on the Prevalence of Surgical Site Infection in Patients With Abdominal Trauma or Acute Surgical Abdomen
This is a Phase IV study designed to evaluate rate of Surgical Site Infections (SSIs) when
the IrriSept device is used in an open abdominal laparotomy for abdominal trauma or acute
surgical abdomen. Half of the eligible subjects will be randomized to receive the IrriSept
device and half of the subjects will receive the respective institution's Standard of Care
(SoC).
the IrriSept device is used in an open abdominal laparotomy for abdominal trauma or acute
surgical abdomen. Half of the eligible subjects will be randomized to receive the IrriSept
device and half of the subjects will receive the respective institution's Standard of Care
(SoC).
IRR-CT-901-2013-01 is a Phase IV, multi-center, prospective, randomized, controlled,
comparator clinical trial. The study consists of 3 parts: a Screening Phase typically
performed in the Emergency Department, a randomized, open-label Treatment (Perioperative)
Phase, and End of Study, a 30-day Follow-up.
Medical Centers throughout the United States will participate as research sites, enrolling
eligible subjects 18 years of age and older who undergo open abdominal laparotomy for
abdominal trauma or acute surgical abdomen. Subjects will be randomized in a 1 - 1 ratio to
receive the IrriSept irrigation device or the institution's Standard of Care (SoC) prior to
abdominal surgery.
Exclusion criteria includes: known allergy to chlorhexidine gluconate (CHG), Abbreviated
Injury Scale (AIS) score of six (6), American Society of Anesthesiologists Physical Status
Classification (ASA) score of five (5) or greater, female subjects who are pregnant and/or
breast feeding, those patients undergoing a damage control laparotomy, abdominal incision
created prior to operating room, and patients enrolled in a concurrent, ongoing
interventional, randomized clinical trial.
Patient risk factors assessed at screening include chronic uncontrolled hypertension,
chronic heart disease, chronic renal disease, chronic pulmonary disease, diabetes mellitus,
HIV, chronic liver disease, a BMI of less than 18 or above 40, coagulopathy, current
long-term steroid use, current smoker, and current cancer. Additional assessments include
PATI (Penetrating Abdominal Trauma Index), AIS and ASA scores, and adherence to SCIP
prophylactic antibiotic-specific guidelines. Other measures to be documented will include
antibiotic usage and surgical skin preparation. The following "present on admission" (PoA)
characteristics will be collected: shock, (systolic BP < 90 mm Hg), intubation, active
infection, transfusion of blood/blood products and primary injury in trauma or primary
organ(s) in the acute abdomen. Intra-operative SSI risk factors including drains, staple
versus sutures, surgical time (skin to skin), blood/blood products, and body temperature
below 36 degrees Celsius will also be evaluated and risk adjusted in the final analysis.
Exploratory endpoints at study completion include: infection (superficial, deep, organ
space), ventilator associated pneumonia (VAP), catheter associated urinary tract infection
(CAUTI), central line associated blood stream infection (CLABSI), deep vein thrombosis
(DVT), pulmonary embolus (PE), acute cardiac event, Clostridium difficile (C-diff)
infection, MRSA infection, mortality and length of stay (LOS).
The Standard of Care (SoC) arm subjects will receive routine surgical Standard of Care
(SoC). It should be noted that routine SoC is at the sole discretion of the investigator and
institution and may or may not involve surgical wound irrigation. If irrigation is used, it
will be delivered by bulb syringe or pour method but not a pressure device, which can range
from a syringe with a cannula to jet lavage.
While the primary objective of this research involves surgical site infections, hospital
readmission rates, hospital costs, and length of hospital stay will also be compared between
the two study arms as secondary objectives.
comparator clinical trial. The study consists of 3 parts: a Screening Phase typically
performed in the Emergency Department, a randomized, open-label Treatment (Perioperative)
Phase, and End of Study, a 30-day Follow-up.
Medical Centers throughout the United States will participate as research sites, enrolling
eligible subjects 18 years of age and older who undergo open abdominal laparotomy for
abdominal trauma or acute surgical abdomen. Subjects will be randomized in a 1 - 1 ratio to
receive the IrriSept irrigation device or the institution's Standard of Care (SoC) prior to
abdominal surgery.
Exclusion criteria includes: known allergy to chlorhexidine gluconate (CHG), Abbreviated
Injury Scale (AIS) score of six (6), American Society of Anesthesiologists Physical Status
Classification (ASA) score of five (5) or greater, female subjects who are pregnant and/or
breast feeding, those patients undergoing a damage control laparotomy, abdominal incision
created prior to operating room, and patients enrolled in a concurrent, ongoing
interventional, randomized clinical trial.
Patient risk factors assessed at screening include chronic uncontrolled hypertension,
chronic heart disease, chronic renal disease, chronic pulmonary disease, diabetes mellitus,
HIV, chronic liver disease, a BMI of less than 18 or above 40, coagulopathy, current
long-term steroid use, current smoker, and current cancer. Additional assessments include
PATI (Penetrating Abdominal Trauma Index), AIS and ASA scores, and adherence to SCIP
prophylactic antibiotic-specific guidelines. Other measures to be documented will include
antibiotic usage and surgical skin preparation. The following "present on admission" (PoA)
characteristics will be collected: shock, (systolic BP < 90 mm Hg), intubation, active
infection, transfusion of blood/blood products and primary injury in trauma or primary
organ(s) in the acute abdomen. Intra-operative SSI risk factors including drains, staple
versus sutures, surgical time (skin to skin), blood/blood products, and body temperature
below 36 degrees Celsius will also be evaluated and risk adjusted in the final analysis.
Exploratory endpoints at study completion include: infection (superficial, deep, organ
space), ventilator associated pneumonia (VAP), catheter associated urinary tract infection
(CAUTI), central line associated blood stream infection (CLABSI), deep vein thrombosis
(DVT), pulmonary embolus (PE), acute cardiac event, Clostridium difficile (C-diff)
infection, MRSA infection, mortality and length of stay (LOS).
The Standard of Care (SoC) arm subjects will receive routine surgical Standard of Care
(SoC). It should be noted that routine SoC is at the sole discretion of the investigator and
institution and may or may not involve surgical wound irrigation. If irrigation is used, it
will be delivered by bulb syringe or pour method but not a pressure device, which can range
from a syringe with a cannula to jet lavage.
While the primary objective of this research involves surgical site infections, hospital
readmission rates, hospital costs, and length of hospital stay will also be compared between
the two study arms as secondary objectives.
Inclusion Criteria:
1. Is male or female, 18 years of age or older
2. Has provided written informed consent or has surrogate consent provide by a Legally
Authorized Representative (LAR)
3. Has experienced abdominal trauma, blunt or penetrating requiring open abdominal
laparotomy with primary closure -or-
4. Has experienced acute surgical abdomen requiring open abdominal laparotomy with
primary closure
Exclusion Criteria:
1. Known allergy to Chlorhexidine Gluconate (CHG)
2. Estimated Abbreviated Injury Scale (AIS) score of six (6) at the time of surgery, for
all trauma patients
3. American Society of Anesthesiologists Physical Status Classification (ASA) score of
five (5) or greater (As ASA scoring is a subjective measure, if the PI finds the
patient stable enough for study participation despite a score of 5, enrollment may
continue)
4. Female volunteers who are pregnant and/or breast feeding
5. Damage control laparotomy
6. Abdominal incision created prior to operating room
7. Currently enrolled in an ongoing, interventional, randomized clinical trial
We found this trial at
18
sites
22 S Greene St
Baltimore, Maryland 21201
Baltimore, Maryland 21201
(410) 328-8667
Principal Investigator: Jose Diaz, MD
Phone: 410-328-5491
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
Click here to add this to my saved trials
1200 N State St Pmb 305
Los Angeles, California 90033
Los Angeles, California 90033
Principal Investigator: Demetrios Demetriades, MD
Phone: 323-409-8587
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Donald Davis, MD
Phone: 813-844-4133
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Lena Napolitano, MD
Phone: 734-936-4212
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
Cincinnati, Ohio 45267
(513) 556-6000
Principal Investigator: Jay Johannigman, MD
Phone: 513-558-6305
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Joseph Minei, MD
Phone: 214-648-6743
Click here to add this to my saved trials
Dayton, Ohio 45409
Principal Investigator: Akpofure Peter Ekeh, MD
Phone: 937-208-4451
Click here to add this to my saved trials
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Laura Moore, MD
Phone: 713-500-5216
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Kent Choi, MD
Phone: 319-356-3890
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Phillip Chang, MD
Phone: 859-218-5152
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
Memphis, Tennessee 38163
Principal Investigator: Martin Croce, MD
Phone: 901-448-1133
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Thomas Carver, MD
Phone: 414-805-6876
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Mark Muir, MD
Phone: 210-743-4149
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Heather Evans, MD
Phone: 206-744-7723
Click here to add this to my saved trials
Baystate Medical Center Baystate Medical Center (BMC), in Springfield, Massachusetts, is an academic, research, and...
Click here to add this to my saved trials
Tucson, Arizona 85724
Principal Investigator: Andrew Tang, MD
Phone: 520-626-2876
Click here to add this to my saved trials